Selected article for: "RNA polymerase and virus infection"
Author: Deval, Jerome; Symons, Julian A; Beigelman, Leo
Title: Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus
  • Cord-id: qovrstak
  • Document date: 2014_9_17
    • ID: qovrstak
    Snippet: A number of important human infections are caused by positive-strand RNA viruses, yet almost none can be treated with small molecule antiviral therapeutics. One exception is the chronic infection caused by hepatitis C virus (HCV), against which new generations of potent inhibitors are being developed. One of the main molecular targets for anti-HCV drugs is the viral RNA-dependent RNA polymerase, NS5B. This review summarizes the search for nucleoside and nucleotide analogs that inhibit HCV NS5B,
    Document: A number of important human infections are caused by positive-strand RNA viruses, yet almost none can be treated with small molecule antiviral therapeutics. One exception is the chronic infection caused by hepatitis C virus (HCV), against which new generations of potent inhibitors are being developed. One of the main molecular targets for anti-HCV drugs is the viral RNA-dependent RNA polymerase, NS5B. This review summarizes the search for nucleoside and nucleotide analogs that inhibit HCV NS5B, which led to the FDA approval of sofosbuvir in 2013. Advances in anti-HCV therapeutics have also stimulated efforts to develop nucleoside analogs against other positive-strand RNA viruses. Although it remains to be validated in the clinic, the prospect of using nucleoside analogs to treat acute infections caused by RNA viruses represents an important paradigm shift and a new frontier for future antiviral therapies.

    Search related documents:
    Co phrase search for related documents
    • activation pathway and liver infection: 1, 2
    • active area and acute infection: 1, 2
    • active area and liver infection: 1
    • active form and acute infection: 1, 2, 3
    • active metabolite and acute infection: 1
    • active metabolite and liver infection: 1
    • active site and acute infection: 1, 2, 3, 4, 5, 6
    • active site and liver infection: 1
    • active site and liver target: 1
    • active site and low bioavailability: 1, 2, 3
    • acute infection and liver infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
    • acute infection and liver target: 1, 2, 3, 4, 5
    • acute infection and low bioavailability: 1, 2, 3
    • acute infection case and liver infection: 1